CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 186 enrolled
Drug / intervention
vigabatrin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00611130
NCT00611130Phase 2Completed

Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study

Catalyst Pharmaceuticals, Inc.·interventional·Posted Feb 8, 2008·Updated Apr 13, 2016

In Brief

A Phase 2 clinical trial evaluating vigabatrin and placebo for Cocaine Dependence. Completed, enrolled 186 participants across 11 sites.

Detailed Summary

The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 8, 2008
Enrollment StartJan 1, 2008
Primary CompletionMay 1, 2009
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.4 years ago

Interventions

vigabatrindrug

Tablets twice a day for 9 weeks

placebodrug

tablets twice daily for 9 weeks